RLMD
Relmada Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
RLMD fundamentals
Relmada Therapeutics (RLMD) released its earnings on Nov 13, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.3 (YoY +58.33%), missed estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.3
+58.33%
Report date
Nov 13, 2025
RLMD Earnings Call Summary for Q3,2025
- Phase II Success: NDV-01 achieves 92% CR rate in NMIBC with no Grade 3+ adverse events, supporting Phase III启动.
- FDA Alignment: Two registrational tracks for high-risk (BCG-unresponsive) and intermediate-risk NMIBC, with trials starting Q2 2026.
- Capital Strength: $100 million financing ensures funding into 2028, enabling sepranolone Phase II and NDV-01 pivotal studies.
- Market Potential: Addressing 48,000 annual high-risk patients and 40,000 intermediate-risk patients, with simplified administration reducing barriers to adoption.
EPS
Revenue
Revenue & Expenses
Key Indicators
Relmada Therapeutics (RLMD) key financial stats and ratios, covering profitability, financial health, and leverage.
Relmada Therapeutics (RLMD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Relmada Therapeutics (RLMD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Relmada Therapeutics (RLMD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Relmada Therapeutics (RLMD) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Relmada Therapeutics (RLMD) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What is the market's earnings forecast for Relmada Therapeutics next quarter?What guidance did Relmada Therapeutics's management provide for the next earnings period?What is the revenue and EPS growth rate for Relmada Therapeutics year over year?What is Relmada Therapeutics's gross profit margin?What were the key takeaways from Relmada Therapeutics's earnings call?Did Relmada Therapeutics beat or miss consensus estimates last quarter?What does Relmada Therapeutics do and what are its main business segments?What were the key takeaways from Relmada Therapeutics’s earnings call?
